undamentalytics Newsletter
Sign in

Relay Therapeutics, Inc. balance sheet

At the end of fiscal 2025, Relay Therapeutics, Inc. had total assets of $621m, total liabilities of $54.3m and shareholders' equity of $567m. It held $84.0m in cash against $0 of debt: net cash of $84.0m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents44828015214412484121
Receivables7500————
Total current assets7709761,020770809578928
Total assets8001,0081,100844871621967
Accounts payable6811914811
Deferred revenue (current)—0——8——
Total current liabilities14246430512651
Total debt0000000
Total liabilities3711115092945477
Shareholders' equity763898950752778567890
Net debt (negative = net cash)−448−280−152−144−124−84−121
Shares outstanding—108m121m127m168m174m219m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: CRBU vs RLAYIRD vs RLAYHYFT vs RLAYRLAY vs SRZN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Relay Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Relay Therapeutics, Inc.